[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 3-day-old neonate with d-TGA, intact ventricular septum, and restrictive PFO presenting with severe cyanosis (SpO2 55%) despite PGE1 infusion. Key discriminating findings: (1) d-TGA with intact septum requires adequate atrial-level mixing for survival, (2) restrictive PFO limits mixing, (3) PGE1 maintains ductal patency but cannot address inadequate atrial communication, (4) hemodynamic stability with adequate biventricular function. The clinical problem is inadequate intracardiac mixing at the atrial level causing life-threatening hypoxemia. Balloon atrial septostomy (B) is the established urgent intervention to enlarge the atrial communication and improve mixing, serving as a bridge to definitive arterial switch operation. This is standard management per current guidelines. Alternative analysis: (A) Arterial switch requires stabilization first and adequate mixing; performing emergently without addressing mixing would be high-risk. (C) ECMO is reserved for refractory cases after septostomy fails or hemodynamic instability. (D) Inhaled nitric oxide does not address the structural mixing problem. (E) Surgical septectomy is more invasive, reserved for failed balloon septostomy. No logical flaws; the keyed answer is uniquely defensible. Medical accuracy is excellent. Minimal fix: None needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 3-day-old neonate with d-TGA, intact ventricular septum, and restrictive PFO presenting with severe cyanosis (SpO2 55%) despite PGE1 infusion. Key discriminating findings: (1) d-TGA with intact septum requires adequate atrial-level mixing for survival, (2) restrictive PFO limits mixing, (3) PGE1 maintains ductal patency but cannot address inadequate atrial communication, (4) hemodynamic stability with adequate biventricular function. The clinical problem is inadequate intracardiac mixing at the atrial level causing life-threatening hypoxemia. Balloon atrial septostomy (B) is the established urgent intervention to enlarge the atrial communication and improve mixing, serving as a bridge to definitive arterial switch operation. This is standard management per current guidelines. Alternative analysis: (A) Arterial switch requires stabilization first and adequate mixing; performing emergently without addressing mixing would be high-risk. (C) ECMO is reserved for refractory cases after septostomy fails or hemodynamic instability. (D) Inhaled nitric oxide does not address the structural mixing problem. (E) Surgical septectomy is more invasive, reserved for failed balloon septostomy. No logical flaws; the keyed answer is uniquely defensible. Medical accuracy is excellent. Minimal fix: None needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a patient on methotrexate presenting with subacute respiratory symptoms, HRCT findings of ground-glass opacities with peribronchovascular consolidation, and BAL showing lymphocytosis with inverted CD4/CD8 ratio (0.5). These findings strongly suggest methotrexate pneumonitis. Key discriminating clues: (1) temporal relationship to methotrexate use, (2) BAL lymphocytosis with CD4/CD8 <1.0, (3) ground-glass opacities in peribronchovascular distribution. Choice C (hypersensitivity pneumonitis pattern) is the established histopathologic correlate of methotrexate lung toxicity, characterized by lymphocytic infiltration, poorly formed granulomas, and interstitial inflammation. Choice D (organizing pneumonia) can occur but is less common. Choice B (DAD) represents acute toxicity rather than the subacute presentation described. Choice A (UIP) would suggest RA-ILD rather than drug toxicity. Choice E (PAP) is unrelated. The item correctly identifies hypersensitivity pneumonitis as the predominant histologic pattern in methotrexate pneumonitis, consistent with medical literature. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a patient on methotrexate presenting with subacute respiratory symptoms, HRCT findings of ground-glass opacities with peribronchovascular consolidation, and BAL showing lymphocytosis with inverted CD4/CD8 ratio (0.5). These findings strongly suggest methotrexate pneumonitis. Key discriminating clues: (1) temporal relationship to methotrexate use, (2) BAL lymphocytosis with CD4/CD8 <1.0, (3) ground-glass opacities in peribronchovascular distribution. Choice C (hypersensitivity pneumonitis pattern) is the established histopathologic correlate of methotrexate lung toxicity, characterized by lymphocytic infiltration, poorly formed granulomas, and interstitial inflammation. Choice D (organizing pneumonia) can occur but is less common. Choice B (DAD) represents acute toxicity rather than the subacute presentation described. Choice A (UIP) would suggest RA-ILD rather than drug toxicity. Choice E (PAP) is unrelated. The item correctly identifies hypersensitivity pneumonitis as the predominant histologic pattern in methotrexate pneumonitis, consistent with medical literature. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes severe preeclampsia with pulmonary edema, preserved EF (65%), grade III diastolic dysfunction, elevated E/e' ratio (18), and low CVP (4 mmHg). Key discriminating findings: (1) preserved systolic function rules out peripartum cardiomyopathy (A); (2) low CVP argues strongly against volume overload (C); (3) echocardiographic findings (grade III diastolic dysfunction, elevated E/e') directly indicate diastolic heart failure; (4) no mention of mitral regurgitation findings (E). The clinical picture fits HFpEF from acute afterload mismatch in severe preeclampsia—hypertensive crisis causes increased afterload, impairing ventricular relaxation and causing elevated filling pressures despite preserved contractility. While endothelial dysfunction (B) does occur in preeclampsia and contributes to capillary leak, the specific echo findings pointing to diastolic dysfunction make D the primary mechanism. The keyed answer (D) is uniquely defensible based on the hemodynamic profile provided. Medical accuracy: The pathophysiology is sound—acute hypertensive crisis in preeclampsia causes afterload mismatch leading to diastolic dysfunction and pulmonary edema with preserved EF. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes severe preeclampsia with pulmonary edema, preserved EF (65%), grade III diastolic dysfunction, elevated E/e' ratio (18), and low CVP (4 mmHg). Key discriminating findings: (1) preserved systolic function rules out peripartum cardiomyopathy (A); (2) low CVP argues strongly against volume overload (C); (3) echocardiographic findings (grade III diastolic dysfunction, elevated E/e') directly indicate diastolic heart failure; (4) no mention of mitral regurgitation findings (E). The clinical picture fits HFpEF from acute afterload mismatch in severe preeclampsia—hypertensive crisis causes increased afterload, impairing ventricular relaxation and causing elevated filling pressures despite preserved contractility. While endothelial dysfunction (B) does occur in preeclampsia and contributes to capillary leak, the specific echo findings pointing to diastolic dysfunction make D the primary mechanism. The keyed answer (D) is uniquely defensible based on the hemodynamic profile provided. Medical accuracy: The pathophysiology is sound—acute hypertensive crisis in preeclampsia causes afterload mismatch leading to diastolic dysfunction and pulmonary edema with preserved EF. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the question asks for mortality benefit, but the keyed answer lacks such evidence. Key stem clues: 67-year-old with severe ischemic cardiomyopathy (EF 25%), CRT-D, post-ablation VT storm despite amiodarone, on GDMT. The question explicitly asks which therapy \\\"has demonstrated mortality benefit in this specific population.\\\" The keyed answer (mexiletine) reduces VT recurrence and ICD shocks per MEXICA trial but has NOT demonstrated mortality benefit. The rationale correctly describes mexiletine's efficacy for VT suppression but conflates arrhythmia reduction with mortality benefit - these are distinct endpoints. None of the listed antiarrhythmics (mexiletine, sotalol, ranolazine, quinidine, dofetilide) have proven mortality benefit in refractory VT populations; some (sotalol, dofetilide) may increase mortality in low-EF patients. If the question asked about \\\"reducing VT recurrence\\\" or \\\"ICD shocks,\\\" mexiletine would be correct. The medical content about mexiletine's mechanism and MEXICA trial is accurate, but the question stem's specific requirement for mortality benefit makes all options indefensible. Minimal fix: Change question to ask \\\"Which therapy has demonstrated reduction in VT recurrence when added to amiodarone?\\\" OR acknowledge no option has mortality benefit and mark as \\\"None of the above.\\\"\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the question asks for mortality benefit, but the keyed answer lacks such evidence. Key stem clues: 67-year-old with severe ischemic cardiomyopathy (EF 25%), CRT-D, post-ablation VT storm despite amiodarone, on GDMT. The question explicitly asks which therapy \"has demonstrated mortality benefit in this specific population.\" The keyed answer (mexiletine) reduces VT recurrence and ICD shocks per MEXICA trial but has NOT demonstrated mortality benefit. The rationale correctly describes mexiletine's efficacy for VT suppression but conflates arrhythmia reduction with mortality benefit - these are distinct endpoints. None of the listed antiarrhythmics (mexiletine, sotalol, ranolazine, quinidine, dofetilide) have proven mortality benefit in refractory VT populations; some (sotalol, dofetilide) may increase mortality in low-EF patients. If the question asked about \"reducing VT recurrence\" or \"ICD shocks,\" mexiletine would be correct. The medical content about mexiletine's mechanism and MEXICA trial is accurate, but the question stem's specific requirement for mortality benefit makes all options indefensible. Minimal fix: Change question to ask \"Which therapy has demonstrated reduction in VT recurrence when added to amiodarone?\" OR acknowledge no option has mortality benefit and mark as \"None of the above.\"", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic PFAPA syndrome: recurrent fever episodes every 4–6 weeks since age 2, with cervical lymphadenopathy, aphthous stomatitis, and pharyngitis; spontaneous resolution within 5 days; complete wellness between episodes; normal growth; elevated inflammatory markers during episodes; normal CBC; and negative genetic testing for other autoinflammatory syndromes (FMF, TRAPS, HIDS). The question asks for treatment with highest likelihood of complete remission. Key discriminating findings: stereotypical periodic episodes, negative genetic testing, and classic tetrad. Keyed answer (D, tonsillectomy) is correct: literature supports 63–95% complete resolution rates, making it the most definitive treatment. Alternative assessments: (A) Colchicine has variable/modest efficacy in PFAPA; (B) Anakinra is effective but reserved for refractory cases and doesn't achieve remission rates comparable to tonsillectomy; (C) Corticosteroids abort individual episodes but may shorten inter-episode intervals and don't provide cure; (E) Cimetidine has inconsistent evidence and lower efficacy. The stem provides sufficient detail to identify PFAPA and select tonsillectomy as offering highest remission likelihood. Medical accuracy is sound, consistent with current pediatric rheumatology literature. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic PFAPA syndrome: recurrent fever episodes every 4–6 weeks since age 2, with cervical lymphadenopathy, aphthous stomatitis, and pharyngitis; spontaneous resolution within 5 days; complete wellness between episodes; normal growth; elevated inflammatory markers during episodes; normal CBC; and negative genetic testing for other autoinflammatory syndromes (FMF, TRAPS, HIDS). The question asks for treatment with highest likelihood of complete remission. Key discriminating findings: stereotypical periodic episodes, negative genetic testing, and classic tetrad. Keyed answer (D, tonsillectomy) is correct: literature supports 63–95% complete resolution rates, making it the most definitive treatment. Alternative assessments: (A) Colchicine has variable/modest efficacy in PFAPA; (B) Anakinra is effective but reserved for refractory cases and doesn't achieve remission rates comparable to tonsillectomy; (C) Corticosteroids abort individual episodes but may shorten inter-episode intervals and don't provide cure; (E) Cimetidine has inconsistent evidence and lower efficacy. The stem provides sufficient detail to identify PFAPA and select tonsillectomy as offering highest remission likelihood. Medical accuracy is sound, consistent with current pediatric rheumatology literature. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes severe Class IV-G lupus nephritis with high activity (40% crescents, activity index 14/24) requiring aggressive induction. Key clues: acute kidney injury, RBC casts, low complement, high anti-dsDNA, diffuse proliferative GN with crescents. The question asks which regimen has \\\"demonstrated superior renal response rates.\\\" Option C (voclosporin+MMF+steroids) is keyed based on AURORA trial showing superiority over MMF+steroids alone. However, Option A (MMF+steroids) and Option B (cyclophosphamide+steroids) are both established first-line induction regimens with decades of evidence and comparable efficacy in Class IV lupus nephritis. The ALMS trial showed MMF and cyclophosphamide had similar complete response rates. The question's phrasing is ambiguous: \\\"superior\\\" could mean (1) superior to placebo/standard care (making A or B correct as proven therapies), or (2) superior head-to-head comparison (but voclosporin was only compared to MMF+steroids, not to cyclophosphamide). For severe crescentic disease, cyclophosphamide remains a standard choice. The item requires assuming \\\"superior\\\" means the newest approved regimen rather than established standard-of-care options. Medical accuracy: The voclosporin data is accurate but the comparative claim is overstated without direct head-to-head trials against cyclophosphamide. Minimal fix: Rephrase to \\\"Which FDA-approved regimen most recently demonstrated improved complete renal response rates compared to standard MMF therapy?\\\"\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes severe Class IV-G lupus nephritis with high activity (40% crescents, activity index 14/24) requiring aggressive induction. Key clues: acute kidney injury, RBC casts, low complement, high anti-dsDNA, diffuse proliferative GN with crescents. The question asks which regimen has \"demonstrated superior renal response rates.\" Option C (voclosporin+MMF+steroids) is keyed based on AURORA trial showing superiority over MMF+steroids alone. However, Option A (MMF+steroids) and Option B (cyclophosphamide+steroids) are both established first-line induction regimens with decades of evidence and comparable efficacy in Class IV lupus nephritis. The ALMS trial showed MMF and cyclophosphamide had similar complete response rates. The question's phrasing is ambiguous: \"superior\" could mean (1) superior to placebo/standard care (making A or B correct as proven therapies), or (2) superior head-to-head comparison (but voclosporin was only compared to MMF+steroids, not to cyclophosphamide). For severe crescentic disease, cyclophosphamide remains a standard choice. The item requires assuming \"superior\" means the newest approved regimen rather than established standard-of-care options. Medical accuracy: The voclosporin data is accurate but the comparative claim is overstated without direct head-to-head trials against cyclophosphamide. Minimal fix: Rephrase to \"Which FDA-approved regimen most recently demonstrated improved complete renal response rates compared to standard MMF therapy?\"", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes septic shock with persistent hypotension (MAP 58 mmHg) despite adequate fluid resuscitation and norepinephrine 0.5 mcg/kg/min. Key discriminating findings: (1) norepinephrine dose at threshold for second-line agent (0.25-0.5 mcg/kg/min per guidelines), (2) hyperdynamic LV with EF 75% indicating preserved cardiac function, (3) small IVC with >50% variation suggesting volume status optimized, (4) elevated lactate indicating ongoing tissue hypoperfusion. The clinical problem is choosing appropriate second-line vasopressor in septic shock. Choice A (vasopressin 0.03 units/min) is guideline-concordant as first second-line agent per Surviving Sepsis Campaign guidelines and VASST trial data. Choice B (epinephrine) is typically third-line and increases lactate. Choice C (phenylephrine) is pure alpha-agonist that may reduce cardiac output in sepsis. Choice D (angiotensin II) is reserved for refractory shock after multiple agents fail. Choice E delays adding second agent unnecessarily when norepinephrine is already at guideline threshold. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, reflecting current sepsis management standards. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes septic shock with persistent hypotension (MAP 58 mmHg) despite adequate fluid resuscitation and norepinephrine 0.5 mcg/kg/min. Key discriminating findings: (1) norepinephrine dose at threshold for second-line agent (0.25-0.5 mcg/kg/min per guidelines), (2) hyperdynamic LV with EF 75% indicating preserved cardiac function, (3) small IVC with >50% variation suggesting volume status optimized, (4) elevated lactate indicating ongoing tissue hypoperfusion. The clinical problem is choosing appropriate second-line vasopressor in septic shock. Choice A (vasopressin 0.03 units/min) is guideline-concordant as first second-line agent per Surviving Sepsis Campaign guidelines and VASST trial data. Choice B (epinephrine) is typically third-line and increases lactate. Choice C (phenylephrine) is pure alpha-agonist that may reduce cardiac output in sepsis. Choice D (angiotensin II) is reserved for refractory shock after multiple agents fail. Choice E delays adding second agent unnecessarily when norepinephrine is already at guideline threshold. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, reflecting current sepsis management standards. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 34-week pregnant patient with cerebral venous thrombosis (CVT), intracerebral hemorrhage, and laboratory findings suggesting HELLP syndrome (thrombocytopenia 82,000, elevated LDH, schistocytes). Key discriminating findings: severe hypertension, CVT with hemorrhagic transformation, and microangiopathic hemolytic anemia. The clinical problem asks for immediate management prioritization. Option A (emergent cesarean then anticoagulation) assumes delivery must precede anticoagulation. Option B (immediate therapeutic anticoagulation) follows standard CVT management, where anticoagulation is indicated even with hemorrhage, and HELLP can be managed medically initially at 34 weeks. Both are defensible: CVT guidelines support immediate anticoagulation regardless of hemorrhage presence, while HELLP management supports delivery as definitive treatment. The stem does not specify fetal status, maternal stability for surgery, or hemorrhage stability—critical details for prioritizing delivery versus anticoagulation. Medical accuracy issue: The rationale incorrectly implies anticoagulation cannot be safely initiated before delivery in HELLP; current evidence supports anticoagulation in CVT with hemorrhage even with thrombocytopenia >50,000. Minimal fix: Add explicit contraindication to anticoagulation (e.g., expanding hemorrhage, platelet count <50,000) or specify maternal/fetal instability requiring emergent delivery.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 34-week pregnant patient with cerebral venous thrombosis (CVT), intracerebral hemorrhage, and laboratory findings suggesting HELLP syndrome (thrombocytopenia 82,000, elevated LDH, schistocytes). Key discriminating findings: severe hypertension, CVT with hemorrhagic transformation, and microangiopathic hemolytic anemia. The clinical problem asks for immediate management prioritization. Option A (emergent cesarean then anticoagulation) assumes delivery must precede anticoagulation. Option B (immediate therapeutic anticoagulation) follows standard CVT management, where anticoagulation is indicated even with hemorrhage, and HELLP can be managed medically initially at 34 weeks. Both are defensible: CVT guidelines support immediate anticoagulation regardless of hemorrhage presence, while HELLP management supports delivery as definitive treatment. The stem does not specify fetal status, maternal stability for surgery, or hemorrhage stability—critical details for prioritizing delivery versus anticoagulation. Medical accuracy issue: The rationale incorrectly implies anticoagulation cannot be safely initiated before delivery in HELLP; current evidence supports anticoagulation in CVT with hemorrhage even with thrombocytopenia >50,000. Minimal fix: Add explicit contraindication to anticoagulation (e.g., expanding hemorrhage, platelet count <50,000) or specify maternal/fetal instability requiring emergent delivery.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 14-year-old with classic SLE features (ANA, anti-dsDNA, anti-Smith, low complements) and active renal involvement (proteinuria, hematuria). The question asks what anti-C1q antibodies most specifically predict. Key discriminating findings: anti-C1q positivity, active urinalysis abnormalities, low C3/C4. Anti-C1q antibodies are well-established markers with high specificity for lupus nephritis, particularly proliferative forms (Class III/IV), with negative predictive values approaching 100%. Option B (proliferative lupus nephritis) is the keyed answer and is strongly supported by current literature showing anti-C1q's specific association with renal disease activity in SLE. Alternative options are less defensible: A (neuropsychiatric lupus) is more associated with anti-ribosomal P antibodies; C (antiphospholipid syndrome) requires antiphospholipid antibodies; D (lupus pneumonitis) and E (autoimmune hemolytic anemia) lack specific association with anti-C1q. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, reflecting current understanding of anti-C1q's role as a biomarker for lupus nephritis. No fix needed; item is well-constructed and educationally sound.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 14-year-old with classic SLE features (ANA, anti-dsDNA, anti-Smith, low complements) and active renal involvement (proteinuria, hematuria). The question asks what anti-C1q antibodies most specifically predict. Key discriminating findings: anti-C1q positivity, active urinalysis abnormalities, low C3/C4. Anti-C1q antibodies are well-established markers with high specificity for lupus nephritis, particularly proliferative forms (Class III/IV), with negative predictive values approaching 100%. Option B (proliferative lupus nephritis) is the keyed answer and is strongly supported by current literature showing anti-C1q's specific association with renal disease activity in SLE. Alternative options are less defensible: A (neuropsychiatric lupus) is more associated with anti-ribosomal P antibodies; C (antiphospholipid syndrome) requires antiphospholipid antibodies; D (lupus pneumonitis) and E (autoimmune hemolytic anemia) lack specific association with anti-C1q. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, reflecting current understanding of anti-C1q's role as a biomarker for lupus nephritis. No fix needed; item is well-constructed and educationally sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The question asks which mechanical circulatory support device provides the greatest degree of LV unloading in refractory cardiogenic shock post-STEMI. Key stem clues: proximal LAD occlusion, extensive akinesis (anterior wall/apex/septum), EF 20%, refractory shock despite dual inotropes/pressors, CI 1.6 L/min/m². The keyed answer (Impella 5.5) is defensible as it provides the highest flow rate (5.5 L/min) and greatest active LV unloading by directly aspirating blood from the LV cavity and ejecting into ascending aorta, reducing LVEDP and wall stress. Alternative analysis: IABP (A) provides minimal support (~0.5 L/min augmentation); Impella CP (B) provides only 3-4 L/min; TandemHeart (C) provides good support but less than Impella 5.5; VA-ECMO (D) provides excellent systemic support but paradoxically increases LV afterload without venting, worsening LV distension. The question specifically asks for 'greatest degree of LV unloading' which is a measurable hemodynamic parameter. Medical accuracy: The explanation correctly describes the hemodynamic profiles of each device and the unique advantage of Impella 5.5 for direct LV unloading. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The question asks which mechanical circulatory support device provides the greatest degree of LV unloading in refractory cardiogenic shock post-STEMI. Key stem clues: proximal LAD occlusion, extensive akinesis (anterior wall/apex/septum), EF 20%, refractory shock despite dual inotropes/pressors, CI 1.6 L/min/m². The keyed answer (Impella 5.5) is defensible as it provides the highest flow rate (5.5 L/min) and greatest active LV unloading by directly aspirating blood from the LV cavity and ejecting into ascending aorta, reducing LVEDP and wall stress. Alternative analysis: IABP (A) provides minimal support (~0.5 L/min augmentation); Impella CP (B) provides only 3-4 L/min; TandemHeart (C) provides good support but less than Impella 5.5; VA-ECMO (D) provides excellent systemic support but paradoxically increases LV afterload without venting, worsening LV distension. The question specifically asks for 'greatest degree of LV unloading' which is a measurable hemodynamic parameter. Medical accuracy: The explanation correctly describes the hemodynamic profiles of each device and the unique advantage of Impella 5.5 for direct LV unloading. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]